Corcept Therapeutics Incorporated

CORT Healthcare Biotechnology

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.

Revenue
+64.0%
EPS
+525.8%
Free cash flow
+161.0%

Quarter to September 2026, against a year earlier

72.30 0.67 +0.94%
Market cap
$7.8B
P/E
47.5×
Fwd P/E
39.8×
Dividend yield
—
F-score
4/9
Altman Z
14.11
Beneish M
−2.76
Dividend safety
n/a

Corcept Therapeutics Incorporated (CORT) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, Corcept Therapeutics Incorporated (CORT) trades at a P/E ratio of 47.5×. Over the past ten years it has ranged from 0.0× (June 2016) to 458× (September 2016); the current reading is higher than 75% of that period. That is above the Biotechnology industry median of 10.3× and above the Healthcare sector median of 25.2×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 37.0× (0.82%)
FY2024 37.3× 59.13%
FY2023 23.5× 10.48%
FY2022 21.2× (6.71%)
FY2021 22.8× (19.96%)
FY2020 28.4× 95.05%
FY2019 14.6× (29.07%)
FY2018 20.6× 28.04%
FY2017 16.1× (84.78%)
FY2016 105× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 75.9× (54.63%)
Jun 2026 167× 86.67%
Mar 2026 89.6× 141.96%
Dec 2025 37.0× (55.46%)
43 more quarters

Against its own ten years

Low 0.0× High 458×
Ten-year median 25.0×
Current reading's percentile 72

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on CORT